Drilldown: Medicines
Medicines > classes 
:
Dissociative or
Opioid or
[[:Category:Antiarrhythmics|Antiarrhythmic (Vaughan-Williams class IC)]]
:
Dissociative or
Opioid or
[[:Category:Antiarrhythmics|Antiarrhythmic (Vaughan-Williams class IC)]] Use the filters below to narrow your results.
generic:
brand:
None (29) ·
(multiple, generic dominant) (1) ·
Alfenta (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Duragesic (1) ·
DXM (1) ·
DXO (1) ·
Heroin (1) ·
Krokodil (1) ·
Nubain (1) ·
Nucynta (1) ·
O-DSMT (1) ·
Opana (1) ·
Spravato (1) ·
Stablon (1) ·
Stadol (1) ·
Sufenta (1) ·
Talwin (1) ·
Tambocor (US brand discontinued) (1) ·
Ultiva (1) ·
Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
uses:
None (48) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-0000113C-QINU`"', '"`UNIQ--vote-0000113D-QINU`"', '"`UNIQ--vote-0000113E-QINU`"' (1)
starting dose:
None (48) ·
50 mg PO BID; titrate to 100-200 mg BID; pill-in-pocket 200-300 mg PO single dose for AF conversion (1) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (48) ·
Avoid; may cause fetal harm (1) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Use in fetal SVT (transplacental antiarrhythmic therapy) is established; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (48) ·
Rx, Schedule III (US). REMS program required. (1) ·
US Schedule II (single-entity); Schedule III–V (combination products by content). (1) ·
[[USLegal:Prescription only|Rx-only]] in US. '''Contraindicated in structural heart disease''' — CAST trial (1989) showed increased mortality from class IC agents in patients with prior MI; modern use is limited to structurally normal hearts'"`UNIQ--ref-00001141-QINU`"' (1)
Showing below up to 51 results in range #1 to #51.